A 45-year-old client with systemic lupus erythematosus (SLE) is admitted to the medical unit with a lupus flare. The client reports severe joint pain, facial rash, and fatigue. Laboratory results show elevated anti-dsDNA antibodies and decreased complement levels (C3 and C4). Which nursing intervention should be the priority?

Clinical Priority: Infection Risk in an SLE Flare

A 45-year-old client with SLE is admitted with an active flare (severe joint pain, malar rash, fatigue). Labs show elevated anti-dsDNA and low C3/C4. The combination of disease-driven complement depletion and the imminent initiation of high-dose corticosteroids/immunosuppressants creates a profound immunocompromised state. The immediate, overarching nursing priority is safety from infection, as sepsis is the leading cause of mortality in this population.

Nursing Actions for Infection Control:

• Strict Hand Hygiene: Ensure all staff, visitors, and the client perform hand hygiene before and after contact.
• Protective Environment: Place the client in a private room if possible. Restrict visitors with any signs of infection. No fresh flowers or live plants.
• Monitoring: Vigilantly assess for subtle signs of infection (low-grade fever, tachycardia) as corticosteroids can mask fever and inflammation. Monitor WBC count with differential.
• Skin Integrity: Perform meticulous skin assessment and care, as the malar rash and potential skin fragility from steroids increase portals of entry for pathogens.
• Invasive Line Care: Use strict aseptic technique for any IV lines or catheters. Advocate for early removal of unnecessary lines.

Symptom Management (Non-Priority but Essential):

• Pain & Fatigue: Administer prescribed analgesics and corticosteroids. Schedule rest periods between activities. Apply cold therapy to inflamed joints, not heat.
• Nutrition: Provide a balanced diet. If on high-dose steroids, monitor blood glucose and restrict sodium to manage fluid retention.

Infection control is the priority because preventing sepsis outweighs managing non-life-threatening symptoms during the critical immunosuppressive treatment window.